UNIVERSITY OF SHEFFIELD

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first-ever human trial of regenerative cell therapy for sensorineural hearing loss, marking a significant milestone in auditory medicine.

Scientists from the University of Sheffield and AstraZeneca developed MapDiff, an AI framework that outperforms existing methods for inverse protein folding, a critical process in designing therapeutic proteins.

The UK DANTE phase III trial found that 80.2% of patients who stopped immunotherapy after 12 months maintained disease control, compared to 87.6% who continued treatment for two years or more.

Researchers from the University of Sheffield and COMSATS University discovered that a deoxyribose sugar gel promotes hair regrowth in mice with testosterone-driven hair loss, matching the effectiveness of minoxidil.

The TRICEPS trial is evaluating a portable device that uses electrical pulses to stimulate the vagus nerve via an earpiece, aiming to improve arm function in stroke patients.

University of Sheffield researchers have developed a new nanoparticle-based immunotherapy that significantly delays resistance to androgen deprivation therapy (ADT) in prostate cancer patients.

The MIROCALS clinical trial demonstrated that low-dose interleukin-2 (IL2LD) is safe and reduced the risk of death by over 40% in approximately 80% of motor neurone disease patients with lower levels of a specific biomarker.